Somatostatin in gastroenterology More studies neededBMJ 1994; 309 doi: https://doi.org/10.1136/bmj.309.6954.604 (Published 03 September 1994) Cite this as: BMJ 1994;309:604
- G L Carlson,
- N A Scott,
- M H Irving,
- J J Sancho,
- A Sitges-Serra
- University of Manchester, Hope Hospital, Salford M6 8HD Department of Surgery, Hospital Universitari del Mar, P Maritim 25-29, 08003 Barcelona, Spain
- University of Melbourne, Department of Surgery, Austin Hospital, Heidelberg, Victoria 3084, Australia Department of Gastroenterology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
EDITOR, - We noted with concern the enthusiasm with which A Shulkes and J S Wilson endorse the use of somatostatin and its analogue octreotide in gastroenterology.1 In particular, we have reservations concerning the reported role of octreotide in the management of enterocutaneous fistula since, despite a successful pilot study,2 more studies seem warranted to clarify the timing and the cost-benefit of such treatment. Indeed, more recent studies of patients with such fistulas have failed …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial